Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 50,852 | 141,561 | 141,810 | 148,462 | 120,798 |
| Depreciation Amortization | 24,451 | 105,012 | 81,157 | 55,684 | 28,995 |
| Income taxes - deferred | -6,360 | -52,087 | -743 | 3,455 | 4,800 |
| Accounts receivable | -138,796 | -82,033 | -53,752 | -92,562 | -54,813 |
| Other Working Capital | -216,642 | -96,383 | -83,239 | -174,766 | -136,692 |
| Other Operating Activity | 212,563 | 159,832 | 83,883 | 70,522 | -8,519 |
| Operating Cash Flow | $-73,932 | $175,902 | $169,116 | $10,795 | $-45,431 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -5,246 | 8,186 | 19,862 | 6,793 | 8,457 |
| PPE Investments | -24,456 | -17,634 | 24,729 | 54,029 | 81,183 |
| Purchase Sale Intangibles | -310 | -10,581 | -9,910 | -2,739 | -1,858 |
| Other Investing Activity | -310 | -10,581 | -9,910 | -2,739 | -1,858 |
| Investing Cash Flow | $-30,012 | $-20,029 | $34,681 | $58,083 | $87,782 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,014 | N/A | -1,635 | -1,122 | -566 |
| Common Stock Issued | 21,169 | 69,333 | 43,866 | 29,493 | 8,235 |
| Other Financing Activity | -60,897 | -87,983 | -71,750 | -65,431 | -32,949 |
| Financing Cash Flow | $-40,742 | $-18,650 | $-29,519 | $-37,060 | $-25,280 |
| Exchange Rate Effect | 229 | 32 | -39 | 708 | 1,093 |
| Beginning Cash Position | 724,531 | 587,276 | 587,276 | 587,276 | 587,276 |
| End Cash Position | 580,074 | 724,531 | 761,515 | 619,802 | 605,440 |
| Net Cash Flow | $-144,457 | $137,255 | $174,239 | $32,526 | $18,164 |
| Free Cash Flow | |||||
| Operating Cash Flow | -73,932 | 175,902 | 169,116 | 10,795 | -45,431 |
| Capital Expenditure | -24,456 | -120,959 | -85,271 | -55,971 | -28,817 |
| Free Cash Flow | -98,388 | 54,943 | 83,845 | -45,176 | -74,248 |